Warm, Mixed, and Drug-Induced Immune Hemolytic Anemia

Warm autoimmune hemolytic anemia (WAIHA) is the most common autoimmune hemolytic anemia in adults. An IgG autoantibody reacts near 37 °C, coats the patient’s red cells, and promotes their removal by splenic and hepatic macrophages. Complement may add to the coating and accelerate clearance.^1,2

Warm autoimmune hemolytic anemia

WAIHA may be primary or associated with an autoimmune disease, lymphoid malignancy, infection, immune deficiency, or another condition. About half of adult cases have an associated condition. The hemolysis can develop gradually or produce a rapid, severe anemia.^1,3

WAIHA is diagnosed when hemolysis accompanies a warm-reactive autoantibody, usually with a DAT positive for IgG with or without C3d, after alloimmune, drug-induced, clinically significant cold, mixed, and nonimmune causes are considered. A C3d-only DAT can occur in WAIHA, but a clinically significant cold antibody must be excluded. DAT positivity without hemolysis does not define AIHA.^1,3,4

The laboratory first establishes shortened red-cell survival. Increased indirect bilirubin and lactate dehydrogenase (LDH), decreased haptoglobin, reticulocytosis, polychromasia, and spherocytes support hemolysis. Reticulocytopenia can occur early or with nutritional deficiency, renal disease, infection, marrow disease, or rare antibody effects on erythroid precursors. An inadequate reticulocyte response during severe anemia signals increased urgency because marrow production is failing to match destruction.^1,3

Hemolysis evidence and the monospecific direct antiglobulin test (DAT) pattern are interpreted together. The diagnostic framework establishes that sequence. The Blood Group Immunology explains IgG behavior, antihuman globulin testing, and complement deposition.

Most WAIHA samples have red cells coated with IgG, with or without C3d. Warm autoantibodies usually react broadly with reagent red cells at the indirect antiglobulin test (IAT) phase because their target is present on most common cells. Reaction strength varies by method; hemolysis findings determine disease activity and severity.^2,3,5

IgG-coated red cells are cleared mainly outside the circulation. Splenic macrophages bind IgG Fc regions and may remove part of the membrane, leaving spherocytes with reduced deformability. Complement fragments provide another macrophage signal. Antibody density, IgG subclass, complement, macrophage activity, and marrow compensation together shape the severity.^1,2

Immunohematologic evaluation

A warm autoantibody can react with the antibody screen, identification panel, autocontrol, and donor cells. This broad pattern can hide an alloantibody formed after transfusion or pregnancy. The transfusion and pregnancy history, previous antibody records, DAT, serum or plasma testing, and eluate findings determine the next studies.^2,5

Adsorption, elution, chemical cell treatment, and genotyping follow validated procedures. The method changes which antigens remain detectable and which antibodies can be excluded. Repeated adsorption also dilutes the specimen and can weaken an alloantibody. The final interpretation must state the studies completed and the residual risk.^2,5

Warm IgG usually does not directly agglutinate cells in routine ABO and D typing. A reactive control or ambiguous D result requires resolution by a validated method. Until the D type is resolved, local policy may direct selection of D-negative red cells. Broad Rh reactivity, a suspected antibody to a high-prevalence antigen, or another complex pattern warrants reference-laboratory support.^2,5

Transfusion support

Early communication gives the clinical service the testing status, expected completion time, historical antibodies, and available unit options. It also gives the transfusion service the current hemoglobin trend, symptoms, pregnancy and transfusion history, and urgency.⁵

When time permits, the laboratory excludes clinically significant alloantibodies and selects ABO-compatible red cells that lack antigens for current and historically documented clinically significant alloantibodies. A patient antigen profile can guide Rh and K matching and broader matching when indicated by prior antibodies or ongoing transfusion needs. The autoantibody may continue to react with every donor unit after this work is complete.^2,5

The phrase “least incompatible” is obsolete. Crossmatch reaction grades against a broadly reactive autoantibody fail to identify a safer unit. Unit selection rests on alloantibody assessment, antigen matching, testing limits, and the documented reason for release.⁵

Life-threatening anemia takes priority over completion of lengthy adsorption or molecular studies. Emergency-release group O red cells may be issued under local policy when the ABO group is unresolved or time is critical. Known clinically significant alloantibodies guide antigen-negative selection when suitable units can be supplied without a dangerous delay. The clinical service determines transfusion need from symptoms, hemodynamic status, comorbidities, and the hemoglobin trend.^2,3,5

The clinical service directs treatment. The laboratory follows hemolysis, defines the immune pattern, searches for an alloantibody, and supplies the safest available red cells when transfusion is ordered.^1,3

Mixed and routine-DAT-negative AIHA

Mixed AIHA requires evidence of both a warm autoantibody and a clinically important cold autoantibody. An IgG-and-C3d DAT pattern provides an entry point because warm IgG can also activate complement. A broadly reactive warm eluate or IAT pattern supports the warm component after the transfusion, pregnancy, and alloantibody context is assessed. Cold reactivity at or above 30 °C is a widely used convention for a pathologic cold component, and laboratory-specific interpretation remains necessary. When thermal testing is unavailable, a titer of at least 1:64 at 4 °C supplies supporting evidence only when interpreted with the complete serologic pattern.^3,6

Common explanations for routine-DAT-negative WAIHA include IgG below the method’s detection limit, low-affinity IgG that dissociates during washing, and red-cell-bound IgA or IgM that routine anti-IgG and anti-C3d do not directly detect. Reference laboratories can use expanded monospecific reagents, column methods, flow cytometry, or quantitative cell-bound immunoglobulin assays. Sensitive methods can reduce specificity, and some cases remain nonreactive across available assays. The diagnosis requires objective hemolysis, assessment of alternative causes, and the complete clinical and serologic pattern.^3,7

Drug-induced immune hemolytic anemia

Drug-induced immune hemolytic anemia (DIIHA) is rare and ranges from compensated hemolysis to abrupt intravascular destruction. A drug investigation is warranted when immune hemolysis has a plausible timing relationship to an exposure and more common causes have been assessed. An isolated positive DAT is not sufficient. The medication history must include prescription and over-the-counter drugs, inpatient and perioperative doses, prior exposure, and recently discontinued drugs.^8,9

Antibiotics are prominent among reported cases. Examples with substantial laboratory evidence include piperacillin, ceftriaxone, cefotetan, and penicillin. Diclofenac and oxaliplatin are important examples from other drug classes. The drugs encountered vary with prescribing patterns and the population studied. A reported association is a signal for investigation; the patient’s hemolysis, exposure timing, serology, and competing causes determine the case interpretation.^9,10,11

Current laboratory classification separates drug-dependent antibodies, drug-independent antibodies, and drug-associated nonimmunologic protein adsorption. Historical names such as “hapten” and “immune complex” remain useful shorthand for test patterns, although the mechanisms overlap.^8,10

Laboratory investigation

1. Establish immune hemolysis and its intravascular or extravascular pattern.
2. Record every recent drug with dose timing, route, previous exposure, perioperative administration, and discontinuation date. Add transfusion, pregnancy, passive-antibody, and antibody-therapy history.
3. Collect EDTA whole blood and serum promptly during the event, ideally before another dose or transfusion, while retaining an earlier pretransfusion specimen when available.
4. Perform the DAT with monospecific anti-IgG and anti-C3d and complete routine alloantibody testing.
5. Use the eluate and transfusion history to assess a warm autoantibody, an alloantibody coating transfused cells, and a drug-dependent pattern. A routine screen or eluate performed without drug can be nonreactive because the antibody requires drug in the test system.
6. Consult a reference laboratory when immune hemolysis has a plausible drug relationship and local testing cannot resolve the pattern, especially with abrupt intravascular hemolysis, kidney injury, recent transfusion, or C3d coating with unrevealing routine studies.

Reference testing compares the patient’s sample with and without drug, using untreated and drug-treated cells plus appropriate control specimens. A relevant metabolite or ex vivo drug antigen may be required. Drug solubility, complement availability, collection timing, and method sensitivity can also affect results, so a negative native-drug study does not exclude DIIHA. Specialized findings support the diagnosis within the complete clinical and laboratory pattern.^8,11

The laboratory must promptly communicate a suspected DIIHA pattern. The clinical service decides whether to stop the implicated drug and selects an alternative. Transfusion support follows the same priority used in other immune hemolytic anemias: assess alloantibodies, select antigen-negative units for any identified alloantibody, and supply emergency red cells when delay poses the greater risk.^5,8

References

1. Michel M, Crickx E, Fattizzo B, Barcellini W. Autoimmune haemolytic anaemias. Nat Rev Dis Primers. 2024;10(1):82. doi:10.1038/s41572-024-00566-2.
2. Bloch EM, Campbell-Lee S, McKenna DH Jr, Montemayor-Garcia C, Schwartz J, Shaz B, Storry J, eds. Technical Manual. 22nd ed. AABB; 2026. Accessed August 28, 2026.
3. Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648. doi:10.1016/j.blre.2019.100648.
4. Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2017;176(3):395-411. doi:10.1111/bjh.14478.
5. Johnson ST, Puca KE. Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies. Hematology Am Soc Hematol Educ Program. 2022;2022(1):96-104. doi:10.1182/hematology.2022000406.
6. Jacobs JW, Raza S, Clark LM, et al. Mixed autoimmune hemolytic anemia: a systematic review of epidemiology, clinical characteristics, therapies, and outcomes. Am J Hematol. 2025;100(8):1397-1407. doi:10.1002/ajh.27721.
7. Kamesaki T, Kajii E. A comprehensive diagnostic algorithm for direct antiglobulin test-negative autoimmune hemolytic anemia reveals the relative ratio of three mechanisms in a single laboratory. Acta Haematol. 2018;140(1):10-17. doi:10.1159/000488753.
8. Leger RM, Arndt PA, Garratty G. How we investigate drug-induced immune hemolytic anemia. Immunohematology. 2014;30(2):85-94. doi:10.21307/immunohematology-2019-102.
9. Maquet J, Lafaurie M, Michel M, Lapeyre-Mestre M, Moulis G. Drug-induced immune hemolytic anemia: detection of new signals and risk assessment in a nationwide cohort study. Blood Adv. 2024;8(3):817-826. doi:10.1182/bloodadvances.2023009801.
10. Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology. 2014;30(2):66-79. doi:10.21307/immunohematology-2019-100.
11. Mayer B, Bartolmäs T, Yürek S, Salama A. Variability of findings in drug-induced immune haemolytic anaemia: experience over 20 years in a single centre. Transfus Med Hemother. 2015;42(5):333-339. doi:10.1159/000440673.